ATE359796T1 - Verwendung von 2-alpha-methyl-19-nor-20(s)-1- alpha,25-dihydroxyvitamin als knochenersatz - Google Patents

Verwendung von 2-alpha-methyl-19-nor-20(s)-1- alpha,25-dihydroxyvitamin als knochenersatz

Info

Publication number
ATE359796T1
ATE359796T1 AT01952566T AT01952566T ATE359796T1 AT E359796 T1 ATE359796 T1 AT E359796T1 AT 01952566 T AT01952566 T AT 01952566T AT 01952566 T AT01952566 T AT 01952566T AT E359796 T1 ATE359796 T1 AT E359796T1
Authority
AT
Austria
Prior art keywords
alpha
bone
compound
dihydroxyvitamin
methyl
Prior art date
Application number
AT01952566T
Other languages
German (de)
English (en)
Inventor
Hector F Deluca
Connie M Smith
Original Assignee
Wisconsin Alumni Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Res Found filed Critical Wisconsin Alumni Res Found
Application granted granted Critical
Publication of ATE359796T1 publication Critical patent/ATE359796T1/de

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22D—CASTING OF METALS; CASTING OF OTHER SUBSTANCES BY THE SAME PROCESSES OR DEVICES
    • B22D17/00—Pressure die casting or injection die casting, i.e. casting in which the metal is forced into a mould under high pressure
    • B22D17/20—Accessories: Details
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22D—CASTING OF METALS; CASTING OF OTHER SUBSTANCES BY THE SAME PROCESSES OR DEVICES
    • B22D17/00—Pressure die casting or injection die casting, i.e. casting in which the metal is forced into a mould under high pressure
    • B22D17/20—Accessories: Details
    • B22D17/22—Dies; Die plates; Die supports; Cooling equipment for dies; Accessories for loosening and ejecting castings from dies
    • B22D17/2236—Equipment for loosening or ejecting castings from dies
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22D—CASTING OF METALS; CASTING OF OTHER SUBSTANCES BY THE SAME PROCESSES OR DEVICES
    • B22D17/00—Pressure die casting or injection die casting, i.e. casting in which the metal is forced into a mould under high pressure
    • B22D17/20—Accessories: Details
    • B22D17/22—Dies; Die plates; Die supports; Cooling equipment for dies; Accessories for loosening and ejecting castings from dies
    • B22D17/24—Accessories for locating and holding cores or inserts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mechanical Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT01952566T 2000-07-14 2001-07-10 Verwendung von 2-alpha-methyl-19-nor-20(s)-1- alpha,25-dihydroxyvitamin als knochenersatz ATE359796T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/616,778 US6306844B1 (en) 1997-03-17 2000-07-14 Use of 2α-methyl-19-nor-20(S)-1α, 25-dihydroxyvitamin D3 to increase bone strength

Publications (1)

Publication Number Publication Date
ATE359796T1 true ATE359796T1 (de) 2007-05-15

Family

ID=24470903

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01952566T ATE359796T1 (de) 2000-07-14 2001-07-10 Verwendung von 2-alpha-methyl-19-nor-20(s)-1- alpha,25-dihydroxyvitamin als knochenersatz

Country Status (16)

Country Link
US (4) US6306844B1 (enExample)
EP (1) EP1305030B1 (enExample)
JP (1) JP4955895B2 (enExample)
KR (1) KR100572958B1 (enExample)
CN (1) CN1250225C (enExample)
AT (1) ATE359796T1 (enExample)
AU (2) AU7330301A (enExample)
BR (1) BR0112453A (enExample)
CA (1) CA2416187A1 (enExample)
DE (1) DE60127964T2 (enExample)
DK (1) DK1305030T3 (enExample)
ES (1) ES2286129T3 (enExample)
IL (2) IL153908A0 (enExample)
MX (1) MXPA03000405A (enExample)
NZ (1) NZ524018A (enExample)
WO (1) WO2002005824A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6392071B1 (en) * 1997-03-17 2002-05-21 Wisconsin Alumni: Research Foundation 26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds
EP1301189A2 (en) * 2000-07-14 2003-04-16 Wisconsin Alumni Research Foundation USE OF 2-METHYLENE-19-NOR-20(S)-1$g(a),25-DIHYDROXYVITAMIN D 3? TO INCREASE BONE STRENGTH
US7858602B2 (en) * 2000-10-16 2010-12-28 Rodriguez Victorio C Therapeutic and prophylactic uses of cell specific carbonic anhydrase enzymes in treating aging disorders due to oxidative stress and as growth factors of stem cells
US20030195175A1 (en) * 2002-03-25 2003-10-16 Deluca Hector F. Use of carbon-2-modified-vitamin D analogs to induce the formation of new bone
ATE346839T1 (de) * 2002-03-29 2006-12-15 Wisconsin Alumni Res Found Ein verfahren zur herstellung von 1-alpha-hydroxy-2-methylen-19-nor-homopregnacal iferol
US6846811B2 (en) * 2002-04-22 2005-01-25 Wisconsin Alumni Research Foundation (20S) 1α-hydroxy-2α-methyl and 2β-methyl-19-nor-vitamin D3 and their uses
JP4469794B2 (ja) 2003-02-25 2010-05-26 神戸天然物化学株式会社 ビタミンｄ誘導体を合成するための新規な中間体
CA2539361A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an estrogen agonist/antagonist
US7214671B2 (en) * 2004-02-19 2007-05-08 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3 for the prophylaxis of bone diseases
AU2005309806B2 (en) * 2004-11-22 2012-03-08 Wisconsin Alumni Research Foundation 2-methylene-19-nor-1alpha-hydroxy-17-ene-homopregnacalciferol and its uses
WO2006096555A1 (en) * 2005-03-04 2006-09-14 Women And Infants Hospital Of Ri, Inc. Compositions and methods for cancer treatment
AU2006242184A1 (en) * 2005-05-03 2006-11-09 Wisconsin Alumni Research Foundation 19,26,27-trinor-1alpha,25-dihydroxyvitamin D3 compounds
US7528122B2 (en) * 2006-02-02 2009-05-05 Wisconsin Alumni Research Foundation Vitamin D analog—NEL, methods and uses thereof
US7803789B2 (en) * 2006-02-02 2010-09-28 Wisconsin Alumni Research Foundation Vitamin D analog—RAK, methods and uses thereof
NZ570814A (en) * 2006-04-06 2011-11-25 Wisconsin Alumni Res Found 2-methylene-1alpha-hydroxy-19,21-dinorvitamin D3 analogs and uses thereof
JP2009532460A (ja) 2006-04-06 2009-09-10 ウイスコンシン アラムニ リサーチ ファンデーション ２−置換−１α，２５−ジヒドロキシ−１９，２６，２７−トリノルビタミンＤ類縁体およびその使用
NZ570815A (en) * 2006-04-06 2012-01-12 Wisconsin Alumni Res Found 19-nor-vitamin D analogs with 1,2,or 3,2 heterocyclic ring
ATE523487T1 (de) * 2006-04-06 2011-09-15 Wisconsin Alumni Res Found 2-methylen-1-alpha-dihydroxy-19,21-dinor-vitami - d3-analoga und ihre anwendung
US8575136B2 (en) * 2006-04-06 2013-11-05 Wisconsin Alumni Research Foundation 2-methylene-1α-hydroxy-18,19,21-trinorvitamin D3 analogs and uses thereof
EP2021321B1 (en) * 2006-04-06 2012-06-20 Wisconsin Alumni Research Foundation 2-methylene-1alpha,25-dihydroxy-18,19,21-trinorvitamin d3 and uses thereof
MX2008012674A (es) * 2006-04-10 2008-10-15 Wisconsin Alumni Res Found Compuestos de 1 a-hidroxi-2-(3'-hidroxipropiliden)-19-nor-vitamina d con una cadena lateral 1,1-dimetilpropilo.
MX2008014418A (es) * 2006-05-15 2008-11-27 Wisconsin Alumni Res Found Administracion pulmonar de la 1 alfa, 25-dihidroxivitamina d3 y co-administracion de la homona paratiroidea o calcitonina.
US7888339B2 (en) * 2008-07-10 2011-02-15 Wisconsin Alumni Research Foundation 2-methylene-20(21)-dehydro-19-nor-vitamin D analogs
US7893043B2 (en) * 2008-07-10 2011-02-22 Wisconsin Alumni Research Foundation 2-methylene-(17Z)-17(20)-dehydro-19,21-dinor-vitamin D analogs
US8222236B2 (en) * 2008-07-10 2012-07-17 Wisconsin Alumni Research Foundation 2-methylene-(20E)-20(22)-dehydro-19-nor-vitamin D analogs
CA2764577C (en) * 2009-08-03 2017-12-19 Wisconsin Alumni Research Foundation Method of preventing renal disease and treating symptoms thereof
ES2437921T3 (es) * 2009-10-21 2014-01-15 Wisconsin Alumni Research Foundation Método para prevenir la diabetes tipo 1
US20110237557A1 (en) * 2010-03-23 2011-09-29 Deluca Hector F Diastereomers of 2-methylene-19-nor-22-methyl-1alpha,25-dihydroxyvitamin d3
US8664206B2 (en) 2010-03-23 2014-03-04 Wisconsin Alumni Research Foundation Diastereomers of 2-methylene-19-nor-22-methyl-1α,25-dihydroxyvitamin D3
US8604009B2 (en) * 2010-03-23 2013-12-10 Wisconsin Alumni Research Foundation (20S)-2-methylene-19-nor-22-dimethyl-1α,25-dihydroxyvitamin D3 and (20R)-2-methylene-19-nor-22-dimethyl-1α,25-hydroxyvitamin D3
US20130295083A1 (en) * 2012-05-02 2013-11-07 Wisconsin Alumni Research Foundation 2a-Methyl-19-nor-(20S)-1a,25-dihydroxyvitamin D3 (2AMD) or 2 methylene-19-nor-(20S)-1a,25-dihydroxyvitamin D3 (2MD) Support Survival and Function of Transplanted Islet Cells In Type 1 Diabetes
HK1206600A1 (en) 2012-06-29 2016-01-15 Wisconsin Alumni Research Foundation USE OF 2-METHYLENE-19-NOR-(20S)-1α,25-DIHYDROXYVITAMIN D3 TO TREAT SECONDARY HYPERPARATHYROIDISM
US10369161B2 (en) 2014-12-30 2019-08-06 Wisconsin Alumni Research Foundation Use of 2-methylene-19-NOR-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat primary hyperparathyroidism
US9539264B2 (en) 2014-12-30 2017-01-10 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism in patients previously treated with calcimimetics
WO2017184262A1 (en) * 2016-04-18 2017-10-26 Wisconsin Alumni Research Foundation Use of 2amd and 2md to treat fibrosis

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2114570B (en) 1981-11-02 1985-08-07 Res Inst Medicine Chem Chemical compounds
US4666634A (en) 1984-12-05 1987-05-19 Chugai Seiyaku Kabushiki Kaisha vitamin D3 derivatives having a substituent at 2-position
GB8904154D0 (en) 1989-02-23 1989-04-05 Leo Pharm Prod Ltd Chemical compounds
NZ232734A (en) 1989-03-09 1991-11-26 Wisconsin Alumni Res Found 19-nor vitamin d derivatives and pharmaceutical compositions
US5246925A (en) 1989-03-09 1993-09-21 Wisconsin Alumni Research Foundation 19-nor-vitamin D compounds for use in treating hyperparathyroidism
CA1333616C (en) 1989-03-09 1994-12-20 Hector F. Deluca 19-nor-vitamin d compounds
AU649057B2 (en) 1990-08-24 1994-05-12 Wisconsin Alumni Research Foundation Methods and compositions containing vitamin D compounds for improvement of skin conditions
ATE173401T1 (de) 1990-09-07 1998-12-15 Wisconsin Alumni Res Found Neue verwendung von 1-alpha-hydroxylierten-19-nor-vitamin-d-verbind ngen zur behandlung von psoriasis
AU650751B2 (en) 1991-05-28 1994-06-30 Wisconsin Alumni Research Foundation Novel synthesis of 19-nor vitamin D compounds
US5086191A (en) 1991-05-28 1992-02-04 Wisconsin Alumni Research Foundation Intermediates for the synthesis of 19-nor vitamin D compounds
JP2898882B2 (ja) 1993-04-05 1999-06-02 ウイスコンシン アラムナイ リサーチ フオンデーシヨン ２−位に置換基を有する１９−ノル−ビタミンｄ３ 化合物
WO1996001811A1 (en) 1994-07-11 1996-01-25 The Johns-Hopkins University 2-substituted 1,25-dihydroxyvitamin d3 derivatives
US5945410A (en) * 1997-03-17 1999-08-31 Wisconsin Alumni Research Foundation 2-alkyl-19-nor-vitamin D compounds
US6316642B1 (en) * 1997-03-17 2001-11-13 Wisconsin Alumni Research Foundation 26,27-Homologated-20-EPI-2alkyl-19-nor-vitamin D compounds
US5962707A (en) * 1998-08-18 1999-10-05 Wisconsin Alumni Research Foundation 19-nor-vitamin D3 compounds with calcemic activity

Also Published As

Publication number Publication date
EP1305030B1 (en) 2007-04-18
AU2001273303B8 (en) 2006-03-09
IL153908A0 (en) 2003-07-31
HK1066487A1 (en) 2005-03-24
BR0112453A (pt) 2003-08-19
DK1305030T3 (da) 2007-09-17
ES2286129T3 (es) 2007-12-01
WO2002005824A1 (en) 2002-01-24
CA2416187A1 (en) 2002-01-24
KR100572958B1 (ko) 2006-04-24
AU2001273303B2 (en) 2006-02-02
JP4955895B2 (ja) 2012-06-20
US20020151528A1 (en) 2002-10-17
CN1250225C (zh) 2006-04-12
US20060003973A1 (en) 2006-01-05
DE60127964D1 (de) 2007-05-31
US6939868B2 (en) 2005-09-06
MXPA03000405A (es) 2003-06-06
KR20030016402A (ko) 2003-02-26
NZ524018A (en) 2006-06-30
CN1501803A (zh) 2004-06-02
EP1305030A1 (en) 2003-05-02
DE60127964T2 (de) 2008-01-17
US20040072804A1 (en) 2004-04-15
IL153908A (en) 2009-08-03
AU7330301A (en) 2002-01-30
US6306844B1 (en) 2001-10-23
JP2004509853A (ja) 2004-04-02

Similar Documents

Publication Publication Date Title
ATE359796T1 (de) Verwendung von 2-alpha-methyl-19-nor-20(s)-1- alpha,25-dihydroxyvitamin als knochenersatz
MXPA03000406A (es) Uso de 2-metilen-19-nor-20(s)-1 alfa,25-dihidroxivitamina d3 para incrementar la resistencia de los huesos.
Andrzejowski et al. The ‘diamond concept’for long bone non-union management
ATE415164T1 (de) (20s)-1alpha-hydroxy-2alpha-methyl und 2beta- methyl-19-nor vitamin d3 und ihre verwendung
MXPA02009590A (es) Compuestos de 2-alquiliden-19-norvitamina d y sus usos terapeuticos.
ATE537834T1 (de) 2-methylen-19-nor-vitamin d2-verbindungen
NZ547930A (en) Set of osteosynthesis plates
Van Lieshout et al. Bone graft substitutes and bone morphogenetic proteins for osteoporotic fractures: what is the evidence?
MY146504A (en) 2-propylidene-19-nor-vitamin d compounds
AR004400A1 (es) Un acido nucleico aislado que codifica un polipeptido comprendiendo por lo menos una de las actividades de la osteoprotegerina (opc), polipeptidos,derivados de dichos polipeptidos, multimeros, vectores, celulas huesped, procedimiento para producir la osteoprotegerina, anticuerpos, metodos de deteccion, composiciones farmaceuticas y usos
AR005987A1 (es) Terapia combinada para la osteoporosis
CA2272745A1 (en) 2-alkyl-19-nor-vitamin d compounds
SG148037A1 (en) Fgf variants and methods for use thereof
NO20004527D0 (no) Modulatorer for proteintyrosinfosfataser (PTPaser)
Hausdorf et al. Stimulation of bone growth factor synthesis in human osteoblasts and fibroblasts after extracorporeal shock wave application
CA2403232A1 (en) 26,27-homologated-20-epi-2-alkyl-19-nor-vitamin d compounds
Compton et al. Skeletal repair in distraction osteogenesis: mechanisms and enhancements
DK1028744T3 (da) Neuronale anvendelser af BMP-11
ATE534623T1 (de) 2-alkyliden-18,19-dinor-vitamin-d-verbindungen
ATE406901T1 (de) Verwendung von mit kohlenstoff-2 modifizierten vitamin-d-analoga zur einleitung der neuen knochenbildung
MX9800801A (es) Proteina mp52 arg humana.
In et al. Cruciate-retaining stemmed total knee arthroplasty for supracondylar-intercondylar femoral fractures in elderly patients: a report of three cases
GB0026114D0 (en) New use
ATE350043T1 (de) 2-methylen-19-nor-20(s)-25-methyl-1alpha- hydroxycalciferol und seine verwendungen
Byalovsky et al. Variable electromagnetic fields in physiotherapy of diseases of the musculoskeletal system

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1305030

Country of ref document: EP